Kissei Pharmaceutical Co(KSPHF)
$24.450.00 (0.00%)
KSPHF
Kissei Pharmaceutical Co financials statements
$24.45
At close:0.00 (0.00%)
Kissei Pharmaceutical Co (KSPHF) Ratios
11 Followers
Kissei Pharmaceutical Co Ratios
KSPHF's free cash flow for Q3 2026 was ¥0.00. For the 2026 fiscal year, KSPHF's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.45 | 5.30 | 5.92 | 6.73 | 5.30 |
| Quick Ratio | 4.95 | 4.12 | 4.43 | 5.20 | 4.29 |
| Cash Ratio | 1.52 | 1.34 | 1.30 | 1.73 | 1.60 |
| Solvency Ratio | 0.49 | 0.42 | 0.39 | 0.55 | 0.46 |
| Operating Cash Flow Ratio | 0.39 | -0.07 | -0.09 | -0.45 | 0.08 |
| Short-Term Operating Cash Flow Coverage | 4.56 | -1.19 | -1.25 | -4.48 | 0.93 |
| Net Current Asset Value | ¥ 73.05B | ¥ 71.42B | ¥ 64.76B | ¥ 74.25B | ¥ 63.43B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.20 | 1.19 | 1.14 | 1.18 |
| Debt Service Coverage Ratio | 11.44 | 14.58 | 11.46 | 9.78 | 10.09 |
| Interest Coverage Ratio | 274.90 | -104.50 | 223.17 | -56.45 | -60.96 |
| Debt to Market Cap | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest Debt Per Share | 37.09 | 30.75 | 30.01 | 32.74 | 36.06 |
| Net Debt to EBITDA | -1.16 | -1.29 | -1.15 | -1.37 | -1.40 |
| Profitability Margins | |||||
| Gross Profit Margin | 49.89% | 47.04% | 49.41% | 47.97% | 47.78% |
| EBIT Margin | 17.70% | 17.37% | 19.14% | 20.30% | 25.28% |
| EBITDA Margin | 22.92% | 22.14% | 24.77% | 26.38% | 30.99% |
| Operating Profit Margin | 6.54% | -3.00% | 5.31% | -1.67% | -2.14% |
| Pretax Profit Margin | 17.67% | 17.34% | 19.12% | 20.27% | 25.25% |
| Net Profit Margin | 13.54% | 14.15% | 14.77% | 15.60% | 19.76% |
| Continuous Operations Profit Margin | 13.56% | 14.33% | 14.94% | 15.76% | 19.93% |
| Net Income Per EBT | 76.63% | 81.58% | 77.24% | 76.96% | 78.28% |
| EBT Per EBIT | 270.38% | -577.27% | 359.70% | -1211.69% | -1177.39% |
| Return on Assets (ROA) | 4.90% | 5.01% | 4.28% | 4.76% | 5.43% |
| Return on Equity (ROE) | 5.72% | 5.99% | 5.07% | 5.43% | 6.42% |
| Return on Capital Employed (ROCE) | 2.54% | -1.15% | 1.65% | -0.55% | -0.64% |
| Return on Invested Capital (ROIC) | 1.93% | -0.95% | 1.28% | -0.42% | -0.50% |
| Return on Tangible Assets | 4.94% | 5.05% | 4.31% | 4.79% | 5.46% |
| Earnings Yield | 7.13% | 7.13% | 7.12% | 8.64% | 10.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.98 | 3.08 | 2.64 | 2.96 | 2.87 |
| Payables Turnover | 9.62 | 7.74 | 7.81 | 7.61 | 8.32 |
| Inventory Turnover | 1.77 | 2.02 | 1.45 | 1.54 | 1.80 |
| Fixed Asset Turnover | 3.26 | 3.47 | 3.04 | 2.75 | 2.72 |
| Asset Turnover | 0.36 | 0.35 | 0.29 | 0.31 | 0.27 |
| Working Capital Turnover Ratio | 1.00 | 1.06 | 0.88 | 0.81 | 0.84 |
| Cash Conversion Cycle | 290.56 | 251.79 | 342.80 | 312.30 | 286.42 |
| Days of Sales Outstanding | 122.53 | 118.34 | 138.50 | 123.33 | 127.32 |
| Days of Inventory Outstanding | 205.97 | 180.57 | 251.01 | 236.95 | 202.98 |
| Days of Payables Outstanding | 37.95 | 47.13 | 46.71 | 47.99 | 43.87 |
| Operating Cycle | 328.50 | 298.92 | 389.51 | 360.29 | 330.30 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 149.49 | -35.73 | -37.05 | -144.83 | 33.24 |
| Free Cash Flow Per Share | 46.17 | -153.22 | -77.56 | -200.07 | -8.37 |
| Dividend Paid and CapEx Coverage Ratio | 0.78 | -0.15 | -0.30 | -1.18 | 0.34 |
| Capital Expenditure Coverage Ratio | 1.45 | -0.30 | -0.91 | -2.62 | 0.80 |
| Operating Cash Flow Coverage Ratio | 4.08 | -1.19 | -1.25 | -4.48 | 0.93 |
| Operating Cash Flow to Sales Ratio | 0.07 | -0.02 | -0.02 | -0.10 | 0.02 |
| Free Cash Flow Yield | 1.20% | -3.29% | -2.24% | -7.58% | -0.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 14.02 | 14.03 | 14.05 | 11.57 | 9.12 |
| Price-to-Sales (P/S) Ratio | 1.90 | 1.98 | 2.07 | 1.80 | 1.80 |
| Price-to-Book (P/B) Ratio | 0.80 | 0.84 | 0.71 | 0.63 | 0.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 83.28 | -30.35 | -44.68 | -13.20 | -305.24 |
| Price-to-Operating Cash Flow Ratio | 25.72 | -130.14 | -93.51 | -18.23 | 76.86 |
| Price-to-Earnings Growth (PEG) Ratio | 1.25 | 0.67 | 1.75 | -0.62 | 0.06 |
| Enterprise Value Multiple | 7.12 | 7.67 | 7.23 | 5.47 | 4.41 |
| Enterprise Value | 144.15B | 165.46B | 135.26B | 97.39B | 89.45B |
| EV to EBITDA | 7.12 | 7.67 | 7.23 | 5.47 | 4.41 |
| EV to Sales | 1.63 | 1.70 | 1.79 | 1.44 | 1.37 |
| EV to Free Cash Flow | 71.58 | -25.98 | -38.54 | -10.56 | -231.74 |
| EV to Operating Cash Flow | 22.11 | -111.42 | -80.66 | -14.58 | 58.35 |
| Tangible Book Value Per Share | 4773.62 | 5523.51 | 4842.06 | 4191.82 | 4350.19 |
| Shareholders’ Equity Per Share | 4791.25 | 5537.41 | 4861.62 | 4204.68 | 4367.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.17 | 0.22 | 0.22 | 0.21 |
| Revenue Per Share | 2024.90 | 2343.63 | 1669.96 | 1463.58 | 1417.78 |
| Net Income Per Share | 274.20 | 331.53 | 246.59 | 228.30 | 280.19 |
| Tax Burden | 0.77 | 0.82 | 0.77 | 0.77 | 0.78 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.15 | 0.00 | 0.13 | 0.15 | 0.16 |
| SG&A to Revenue | 0.25 | 0.50 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.55 | -0.11 | -0.15 | -0.49 | 0.09 |
Currency in JPY
